Foxconn (Far East) Limited to Acquire Major Stake in Maxnerva Technology Services Limited and Launch Mandatory Cash Offers

Key Details of the Transaction

• Foxconn (Far East) Limited (“Offeror”) has entered into a conditional share purchase agreement (SPA) to acquire a 33.85% stake (239,050,141 shares) in Maxnerva Technology Services Limited (“Maxnerva”) for HK\$152,370,559 in cash (HK\$0.6374 per share).
• The SPA was signed on July 27, 2026, after trading hours. Sellers are FSK Holdings Limited (“FSK”) and FDG Fund, L.P. (“FDG Fund”), both concert parties of Foxconn.
• Upon SPA completion, Foxconn will directly hold 285,730,141 shares, representing 40.46% of Maxnerva’s issued share capital. FSK and FDG Fund will exit their positions completely.
• Following SPA completion, Foxconn will be required to make a mandatory conditional cash offer (“Share Offer”) for all remaining Maxnerva shares not already owned or agreed to be acquired by the Offeror or its concert parties, at the same price of HK\$0.6374 per share.
• Foxconn will also make an offer to cancel all outstanding options at “see-through” prices based on the exercise price of each option.

Price-Sensitive and Shareholder-Impacting News

• The Share Offer price represents a significant premium to recent trading prices:
  • 55.46% premium over the last closing price of HK\$0.4100 per share before announcement.
  • Premiums of 56.23%, 57.38%, and 43.66% over the 5-day, 10-day, and 30-day average closing prices, respectively, preceding the announcement.
• The offer price is at a 3.7% discount to the company’s audited net asset value per share as of December 31, 2025 (RMB 0.5732, equivalent to HK\$0.6619).
• The maximum cash consideration for full acceptance of both the Share Offer and Option Offer could reach approximately HK\$272.34 million.
• The offers are conditional on completion of the SPA and on Foxconn and its concert parties gaining control of more than 50% of Maxnerva’s voting rights via valid acceptances.
• There is a risk that the SPA and the Offers may not complete if conditions are not met, including regulatory approval from the Vietnam Competition Commission and no material adverse events.
• Foxconn intends to maintain Maxnerva’s listing status on the Hong Kong Stock Exchange and ensure adequate public float post-offer, but also reserves the right to review and possibly change Maxnerva’s business, structure, or management after acquisition.
• All directors nominated by FSK, which is a seller and concert party, will not be involved in the independent board committee reviewing the offer.
• Shareholders should be aware that, if the Offer is successful, Foxconn will have controlling influence over Maxnerva, which could impact future strategy and operations.

Other Important Information for Shareholders and Optionholders

• All outstanding options (6,820,000 in total) will be subject to a cash offer at:
  • HK\$0.0001 per option for options exercisable at HK\$1.684 and HK\$0.686.
  • HK\$0.3274 per option for options exercisable at HK\$0.310.
• The SPA can be terminated before completion under several conditions, such as:
  • Mutual agreement.
  • 20-day average share price falls below HK\$0.396 or rises above HK\$1.26.
  • Regulatory approval is not granted, or material warranties are breached.
• Foxconn confirms it has sufficient internal financial resources to complete the acquisition and offers.
• The Composite Document detailing the offer, along with independent recommendations, will be dispatched to shareholders and optionholders no later than 21 days after the announcement, or up to January 15, 2027, depending on SPA completion.
• Shareholders are strongly cautioned that the offers are subject to the completion of the SPA and other conditions, and may or may not proceed.

Company Performance Summary

• Recent audited financials for Maxnerva (RMB ‘000):
  • 2025 Revenue: 707,576 | Net loss: 14,551 | Net assets: 404,807
  • 2024 Revenue: 558,939 | Net loss: 12,443 | Net assets: 424,913
  • 2023 Revenue: 677,877 | Net loss: 16,831 | Net assets: 436,451
• Maxnerva’s business focuses on IT products, software sales, and IT solutions in the PRC, Taiwan, Vietnam, and the US.

Strategic Intentions and Post-Acquisition Plans

• Foxconn’s acquisition is positioned as a long-term investment aimed at simplifying Maxnerva’s shareholding structure and improving operational efficiency.
• Foxconn will perform a strategic review post-acquisition and may make changes to optimize Maxnerva’s business and operations.
• No immediate major changes to business operations, asset deployment, or employment are planned outside ordinary operations.
• The Offeror intends to maintain Maxnerva’s listing and ensure compliance with public float requirements.

Shareholding Structure Before and After the SPA

Risks and Warnings to Investors

• The Offers are subject to completion of the SPA and satisfaction of all conditions. There is no guarantee the Offers will be made.
• Shareholders and Optionholders are urged to exercise caution in dealing with Maxnerva securities and to consult professional advisers if in doubt.
• Further announcements, including independent board committee and financial adviser recommendations, will be issued in due course.

Disclaimer

This article is for information purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should refer to the official announcement and consult professional advisers before making any investment decisions. The information provided is based on the official company announcement and may be subject to change.

鴻海（遠東）有限公司收購雲智匯科技服務有限公司主要股份及提出強制性現金要約

交易重點

• 鴻海（遠東）有限公司（「要約人」）已簽署有條件股份購買協議（SPA），以現金HK\$152,370,559（每股HK\$0.6374）收購雲智匯科技服務有限公司（「雲智匯」）33.85%股權（239,050,141股）。
• 協議於2026年7月27日收市後簽訂，賣方為FSK控股有限公司（「FSK」）及FDG Fund, L.P.（「FDG Fund」），均為鴻海的協同行動方。
• SPA完成後，鴻海將直接持有285,730,141股，佔雲智匯已發行股本的40.46%，FSK及FDG Fund將完全退出持股。
• SPA完成後，鴻海需根據香港收購守則第26.1條，對所有未由要約人或協同行動方持有的雲智匯股份提出強制性現金要約（「股份要約」），要約價同為每股HK\$0.6374。
• 鴻海亦會根據期權行使價，向所有未行使的期權提出「看穿價」現金收購建議。

對股東具重要性及或影響股價的重點

• 股份要約價較公告前最後收市價（HK\$0.4100）溢價55.46%，較過去5日、10日、30日平均收市價分別溢價56.23%、57.38%及43.66%。
• 要約價較2025年12月31日經審核每股資產淨值（HK\$0.6619）折讓約3.7%。
• 若股份及期權全部被接納，最高現金代價約為HK\$2.7234億。
• 股份要約須在SPA完成後並且鴻海及協同行動方持股達公司超過50%才會生效。
• SPA及要約能否完成，取決於越南競爭委員會審批及無重大不利事件等多項條件，存在不確定性。
• 鴻海表示，完成後將維持雲智匯在聯交所上市地位，並確保足夠公眾持股，但會進行策略檢討，或會調整集團業務、架構或管理層。
• FSK提名的三名董事不會參與獨立董事委員會審議。
• 要約成功後，鴻海將掌控雲智匯，未來策略和營運或受影響。

其他股東及期權持有人須知

• 6,820,000份未行使期權將按以下價錢現金收購：
  • 行使價HK\$1.684及HK\$0.686：每份HK\$0.0001
  • 行使價HK\$0.310：每份HK\$0.3274
• SPA完成前可於多種情況下終止，包括：
  • 雙方同意
  • 20日平均股價低於HK\$0.396或高於HK\$1.26
  • 未獲監管批准或保證條款被違反
• 鴻海確認有足夠內部資金完成收購及要約。
• 要約詳情及建議將於公告21日內或最遲2027年1月15日前發出（視乎SPA完成日期）。
• 股東應注意，要約是否進行存不確定性。

公司近年表現摘要

• 雲智匯近年經審核財務數據（人民幣’000）：
  • 2025年收入：707,576｜淨虧損：14,551｜淨資產：404,807
  • 2024年收入：558,939｜淨虧損：12,443｜淨資產：424,913
  • 2023年收入：677,877｜淨虧損：16,831｜淨資產：436,451
• 集團主力於中國、台灣、越南及美國從事IT產品、軟件銷售及解決方案。

策略意向與收購後計劃

• 鴻海收購為長線投資，旨在簡化雲智匯股權結構，提升營運決策效率。
• 收購後鴻海將檢討集團資產、結構及業務，或會作優化調整。
• 除正常業務外，暫無計劃大幅改動集團業務、資產部署或僱員。
• 會維持上市地位及公眾持股比例。

收購前後主要股東結構

投資者須注意風險

• SPA及要約能否完成存不確定性，並非必然達成。
• 股東及期權持有人應審慎處理股份或期權，如有疑問應諮詢專業人士。
• 公司將適時公布獨立董事委員會及財務顧問建議。

免責聲明

以上內容僅供資訊參考，並非投資建議或買賣證券之建議。投資者應參閱公司正式公告及徵詢專業意見再作決定。資料來自官方公告，或有變動。

View MAXNERVA TECH Historical chart here